Altimmune

Akero Therapeutics

This company develops metabolic disease treatments for patients with metabolic dysfunction-associated steatohepatitis and other liver conditions.

Inventiva

This biopharmaceutical company develops oral small molecule therapies for patients with metabolic dysfunction-associated steatohepatitis and other fibrotic or metabolic diseases.

Alveus Therapeutics

This clinical-stage biotechnology company develops next-generation therapies for obesity and metabolic diseases to provide sustained weight loss for patients.

Ousia Pharma

This biotechnology company develops peptide-drug conjugates to treat obesity and cardiometabolic diseases for patients requiring improved metabolic health and weight regulation.

Alba Therapeutics Corp

This biopharmaceutical company develops oral peptide therapeutics to treat autoimmune and inflammatory conditions, such as celiac disease, for patients with gastrointestinal disorders.

AKRO

This company develops injectable medicines to treat patients with serious metabolic diseases, primarily metabolic dysfunction-associated steatohepatitis.

Zealand Pharma

This biotechnology company develops peptide-based medicines for patients with obesity, rare diseases and chronic inflammation through metabolic health research.

89bio (NASDAQ: ETNB)

This biopharmaceutical company develops pegozafermin to treat patients with liver and cardio-metabolic diseases, including metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.